Reneuron Group PLC’s Catherine Isted on the business model, cash runway and its two legacy products

ReNeuron Group PLC’s chief executive-elect Catherine Isted joined Proactive to talk about her last ten months in the job, working to refine the strategic and operational focus of the company.

The company is now fully focused on its proprietary exosomes platform following a strategic review in January that saw it halt its Retinitis Pigmentosa programme.

Isted, who is currently ReNeuron’s chief financial officer, explained the business model, cash position and runway as well its key goals for the next six months.

Pre-clinical data already announced has shown that the company’s exosome drug delivery technology can effectively deliver therapeutic proteins to the brain to potentially treat neurological diseases.

© 2022 The Latest StockMarket News and Interviews